CSL Behring
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, CSL Behring sits in the top decile of US sponsors by registered trial count (#303 of 15,742 sponsors by registered trial count).
CSL Behring: 71 sponsored US clinical trials, 12 recruiting.
CSL Behring sponsors 71 registered US clinical trials on ClinicalTrials.gov, 12 of them currently recruiting, and 49 completed. 35 of these trials are in Phase 3-4 (later-stage) and 28 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hemophilia B, with 3 trials.
Top-decile sponsor footprint
CSL Behring ranks in the top decile of sponsors by registered trial count (#303 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
49 of 58 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
71 total, page 2 of 2
An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A
NCT01486927
A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B
NCT01496274
Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy
NCT01490450
Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects
NCT01403064
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
NCT01373151
Retrospective Chart Review of Subcutaneous IgG Use in Infants
NCT01166074
Patient Registry Study of Berinert® in Normal Clinical Practice
NCT01108848
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
NCT00945906
A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
NCT00885742
A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII Deficiency
NCT00883090
An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N (Kcentra) Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure
NCT00803101
Rabies Immune Plasma Booster Study
NCT01063140
Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy
NCT00708435
Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)
NCT00719680
Human Fibrinogen - Pharmacokinetics
NCT00496262
Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy
NCT00419341
Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency
NCT00261833
Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)
NCT00322556
C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)
NCT00292981
Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks
NCT00168103
Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)
NCT00168090
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 22 |
| Phase 3 | 29 |
| Phase 4 | 6 |
Therapeutic Areas
What is open in the CSL Behring pipeline
12 recruiting of 71 indexed (17% open); 49 completed (69%).
Phase mix: 35 late (III/IV) vs 28 early (I/II) (balanced across stages).
Top condition: Hemophilia B (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
CSL Behring: open-pipeline peers nationwide
Peers matched on 71 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
CSL Behring sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 71 trials (± recruiting share)
- EMD Serono · 71 trials · 0% recruiting
- Nova Southeastern University · 71 trials · 21% recruiting
- H. Lundbeck A/S · 72 trials · 7% recruiting
- Smith & Nephew · 72 trials · 4% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Penn State University · 17% recruiting · 219 trials
- University of Hawaii · 17% recruiting · 77 trials
- NYU Langone Health · 17% recruiting · 1,164 trials
- University of Utah · 17% recruiting · 818 trials
Related
What to do with this CSL Behring page
71 registered trials is a research-attention snapshot, not an endorsement of CSL Behring or any single study.
- 12 of CSL Behring's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Hemophilia B is the condition CSL Behring studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hemophilia B trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
CSL Behring pipeline card: 71 registered trials from official public datasets.Report a data error.